About the Company
Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. As of 2020 the company had approximately 48,000 employees, and it generated more than $7.7 billion in revenue in 2019. The company offers access to diagnostic testing services for cancer, cardiovascular disease, infectious disease, neurological disorders, COVID-19, and employment and court-ordered drug testing.
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $DGX News
Decoding Quest Diagnostics Inc (DGX): A Strategic SWOT Insight
Quest Diagnostics Inc demonstrates robust financial performance with significant revenue from its DIS business. Recent ...
Quest Diagnostics raises 2024 profit and revenue forecast on strong demand
Laboratory operator Quest Diagnostics raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter ...
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic
Quest Diagnostics Inc (NYSE:DGX) posted first-quarter adjusted EPS of $2.04, beating the consensus of $1.86. Sales came in at ...
Labcorp beats quarterly estimates on strong testing demand
Labcorp beat Wall Street expectations for first-quarter profit on Thursday, as growing demand for specialty tests boosted ...
Quest Diagnostics Q1 2024 Earnings: Aligns with Analyst EPS Projections, Raises Full-Year Guidance
Adjusted Full-Year EPS Guidance: Now expected to be between $8.72 and $8.97, an adjustment from earlier projections.
Quest Diagnostics Incorporated (NYSE:DGX) Q1 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE: DGX) Q1 2024 Earnings Call Transcript April 23, 2024 Quest Diagnostics Incorporated ...
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Quest Diagnostics DGX is set to release first-quarter 2024 results on Apr 23 before the opening bell. The company posted ...
Quest Diagnostics: Strong Q1 Outperformance Spurs Buy Rating and Raised Full-Year Guidance
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Quest Diagnostics (DGX – Research ...
Company developing early cancer-detection tests to cut 20% of workforce
Early cancer-detection test maker that raised $254 million earlier this year now says it will cut more than 100 jobs — about ...
Quest adds pTau217 to Alzheimer’s test portfolio
Quest Diagnostics Inc. expanded its Alzheimer’s disease (AD) portfolio with a blood-based biomarker test for phosphorylated ...
Quest Diagnostics: Q1 Earnings Snapshot
Quest Diagnostics expects full-year earnings in the range of $8.72 to $8.97 per share, with revenue in the range of $9.4 billion to $9.48 billion. A new look for Starbucks, regulating AI, a 'Star Trek ...
Q1 2024 Quest Diagnostics Inc Earnings Call
Stephanie July Davis; MD & Senior Research Analyst; Barclays Bank PLC, Research Division ...
Loading the latest forecasts...